Anshul Maheshwari, Chief Financial Officer (CFO) of SI-BONE, Inc. (NASDAQ:SIBN), executed transactions involving a total sale of 4,666 shares of the company’s common stock on May 18, 2026. The sales spanned multiple price points, ranging from $14.35 to $14.84 per share, resulting in an aggregate value of $68,523.
It is important to note the nature of these dispositions. These transactions were explicitly conducted to fulfill tax withholding requirements associated with the vesting of restricted stock units. Consequently, this activity qualifies as a 'sell to cover' transaction and does not represent a discretionary decision by Mr. Maheshwari regarding his personal holdings in SI-BONE.
The executed sale prices are noted to be in close proximity to SI-BONE’s prevailing stock price of $14.82. However, the company has recently faced market headwinds, evidenced by shares being down approximately 25% year-to-date. Despite this short-term decline, an analysis provided by InvestingPro suggests that the stock may currently appear overvalued at its existing levels. Nevertheless, analysts continue to maintain a positive or bullish outlook on the company, setting price targets within a range spanning from $18 to $32.
The sales were not executed in a single block but rather through two distinct transactions occurring on the same day. The initial sale involved 2,477 shares, transacted at a weighted average price of $14.7132 per share. Subsequently, a second transaction accounted for 2,189 shares, sold with a calculated weighted average price of $14.6545 per share.
Following the completion of these sales, Mr. Maheshwari's direct ownership stake in SI-BONE common stock stands at 259,877 shares. This current total includes an addition of 1,395 shares that were acquired under the terms of the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2026. Furthermore, his holdings include 183,921 shares which are issuable upon the settlement of restricted stock units (RSUs), where each unit represents a contingent right to receive one share of the company’s common stock.
These insider transactions occurred against a backdrop of recent operational and financial updates for SI-BONE, Inc. The company reported its first-quarter 2026 financial results, which indicated a performance that was stronger than market expectations in certain areas. Specifically, the company posted an earnings per share (EPS) figure of -$0.10. This result surpassed the forecasted EPS of -$0.19.
In terms of revenue, SI-BONE reported $52.6 million, which fell slightly short of the anticipated $52.85 million mark. Despite this minor shortfall in top-line figures, the company took steps to raise its forward revenue guidance, aligning this updated projection with the positive trend shown during the first quarter's beat. Additionally, SI-BONE bolstered its financial outlook by increasing its gross margin guidance by 100 basis points. This enhancement was attributed to an improved average selling price mix within the business.
The ongoing analyst coverage also reflects this sustained investor attention. In related developments, Truist Securities adjusted its existing price target for SI-BONE shares. The firm lowered its previous price target from $20 down to $18, while simultaneously maintaining a 'Buy' rating on the stock. This adjustment by the brokerage followed the company’s issuance of conservative guidance despite the recent positive financial achievements reported.
Risks
- The stock has experienced a significant downturn of approximately 25% year-to-date.
- Truist Securities lowered its price target for SI-BONE shares from $20 to $18 following the company's conservative guidance.
More from Insider Trading
Risks
- The stock has experienced a significant downturn of approximately 25% year-to-date.
- Truist Securities lowered its price target for SI-BONE shares from $20 to $18 following the company's conservative guidance.